European equities traded in the US as American depositary receipts were moving sharply higher late Wednesday morning, rising 1.59% to 1,445.87 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by software firm SAP (SAP) and biopharmaceutical firm Grifols (GRFS), which rose 3.9% and 3.7%, respectively. Semiconductor company Sequans Communications (SQNS) and kidney dialysis company Fresenius Medical Care (FMS) added 3.2% and 2.8%, respectively.
The decliners from continental Europe were led by biopharmaceutical firm Genfit (GNFT) and pharmaceutical firm Ascendis Pharma (ASND), which both retreated 4.7%. Biopharmaceutical company Cellectis (CLLS) was also down 2.8% and furniture maker Natuzzi (NTZ) declined 2.2%.
From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Mereo BioPharma Group (MREO), which climbed 12% and 9.7% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Amarin Corporation (AMRN), which were up 6.9% and 2.8% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX), which fell 6.1%, while biotech firm Autolus Therapeutics (AUTL) declined 4.5%. They were followed by pharmaceutical company Silence Therapeutics (SLN) and telecommunications operator Vodafone Group (VOD), which were down 1.4% and 0.3% respectively.
Comments